Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Patches Together Strong Sales Growth With Ortho EVRA, Duragesic

Executive Summary

J&J will step up promotion of Ortho EVRA in the fourth quarter, marking the end of supply constraints for the contraceptive patch

You may also be interested in...



J&J Will Maintain Rx Headcount Through 2004 Under Cost-Cutting Plan

Johnson & Johnson expects its pharmaceutical employee headcount to remain constant in 2004

J&J Will Maintain Rx Headcount Through 2004 Under Cost-Cutting Plan

Johnson & Johnson expects its pharmaceutical employee headcount to remain constant in 2004

Mylan Plans Launch Of Generic Duragesic Despite Pediatric Exclusivity

Mylan is planning to launch its generic fentanyl transdermal system by July, the date of the original patent expiration for Alza's Duragesic, despite the product's six-month pediatric exclusivity extension

Related Content

UsernamePublicRestriction

Register

LL1135495

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel